METAP2 and Insulin resistance: Consistent with known effects of METAP2 inhibition, patients with baseline insulin resistance (fasting insulin >20 mU/mL; n = 11) exhibited decreased fasting insulin after treatment with evexomostat, and a subset of those patients (n = 7) for whom time-matched fasting insulin and fasting glucose were available showed marked improvements in their insulin resistance, based on a decline in the homeostatic model assessment of insulin resistance (HOMA-IR) score (Fig. 4E and F).